Arcutis Director Sells $121,000 Amid ZORYVE Revenue Surge
A biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
Determine the index fund with the lowest retirement cost through a concise comparison to guide a cost-aware choice.
28,256 articlesA biotech insider sale of about $121,000 sits beside a strong ZORYVE revenue story. This article breaks down what it ...
Eli Lilly shares surged to fresh highs, underpinned by upbeat analyst notes and strong pipeline momentum. This guide ...
An insider move at a biotech stage company can spark questions. This article breaks down the trade, its timing, and w...
A new framework around Michael Saylor's strategy approach reshapes how Bitcoin is bought and sold. This article unpac...
Many investors sit on cash waiting for rates to fall. This guide shows why stopping the wait and locking in 4% on new...
An in-depth look at Workhorse's path in 2026, focusing on earnings potential, drivers, and strategies for investors n...
Portfolio manager Ben Carlson argues that avoiding big-ticket upgrades can shield households and portfolios from infl...
As 5G and fiber roll out, investors must weigh income vs. growth. This guide compares AT&T and Verizon on dividends, ...
Stocks wiggle as CoreWeave drops on news of Blue Owl’s failed $4B debt placement. Experts say the financing hiccup co...
A practical, reader-friendly guide to what to expect in evaxion (evax) 2025 earnings. Learn the drivers, read the cal...
Adobe stock dropped after earnings despite solid results, leaving many investors puzzled. This article unpacks the fo...
The federal debt breached $39 trillion this week as lawmakers debated a constitutional fix that failed to pass. The p...